Evidence map›Paper›PMID 26087072›Full record

ArticlePloS one2015

Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein.

Russell Vassell, Yong He, Prasad Vennakalanti, Antu K Dey, Min Zhuang, Wei Wang, Yide Sun, Zohar Biron-Sorek, Indresh K Srivastava, Celia C LaBranche and 3 more

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Russell VassellCenter for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.
Yong HeCenter for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.
Prasad VennakalantiCenter for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.
Antu K DeyNovartis Vaccines and Diagnostics, Cambridge, Massachusetts, United States of America.
Min ZhuangCenter for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America; Department of Microbiology, Harbin Medical University, Heilongjiang, China.
Wei WangCenter for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.
Yide SunNovartis Vaccines and Diagnostics, Cambridge, Massachusetts, United States of America.
Zohar Biron-SorekNovartis Vaccines and Diagnostics, Cambridge, Massachusetts, United States of America.
Indresh K SrivastavaNovartis Vaccines and Diagnostics, Cambridge, Massachusetts, United States of America.
Celia C LaBrancheDepartment of Surgery, Duke Medical Center, Durham, North Carolina, United States of America.
David C MontefioriDepartment of Surgery, Duke Medical Center, Durham, North Carolina, United States of America.
Susan W BarnettNovartis Vaccines and Diagnostics, Cambridge, Massachusetts, United States of America.
Carol D WeissCenter for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.

Funding

Vaccine TechnologiesP01AI066287 · NIAID · NOVARTIS VACCINES AND DIAGNOSTICS, INC. · PI BARNETT, SUSAN W · 2006 to 2010
$21.3M
NIAID NIH HHS P01 AI066287NIAID NIH HHS P01AI066287
6 · The paper itself

Abstract

The membrane proximal external region (MPER) of the gp41 subunit of the HIV-1 envelope glycoprotein (Env) contains determinants for broadly neutralizing antibodies and has remained an important focus of vaccine design. However, creating an immunogen that elicits broadly neutralizing antibodies to this region has proven difficult in part due to the relative inaccessibility of the MPER in the native conformation of Env. Here, we describe the antigenicity and immunogenicity of a panel of oligomeric gp41 immunogens designed to model a fusion-intermediate conformation of Env in order to enhance MPER exposure in a relevant conformation. The immunogens contain segments of the gp41 N- and C-heptad repeats to mimic a trapped intermediate, followed by the MPER, with variations that include different N-heptad lengths, insertion of extra epitopes, and varying C-termini. These well-characterized immunogens were evaluated in two different immunization protocols involving gp41 and gp140 proteins, gp41 and gp160 DNA primes, and different immunization schedules and adjuvants. We found that the immunogens designed to reduce extension of helical structure into the MPER elicited the highest MPER antibody binding titers, but these antibodies lacked neutralizing activity. The gp41 protein immunogens also elicited higher MPER titers than the gp140 protein immunogen. In prime-boost studies, the best MPER responses were seen in the groups that received DNA priming with gp41 vectors followed by gp41 protein boosts. Finally, although titers to the entire protein immunogen were similar in the two immunization protocols, MPER-specific titers differed, suggesting that the immunization route, schedule, dose, or adjuvant may differentially influence MPER immunogenicity. These findings inform the design of future MPER immunogens and immunization protocols.

Indexed as

AIDS VaccinesAnimalsAntibodies, MonoclonalEnzyme-Linked Immunosorbent AssayHIV-1HIV AntibodiesHIV Envelope Protein gp41Neutralization TestsProtein ConformationRabbitsVaccines, SyntheticViral Fusion ProteinsAIDS VaccinesAntibodies, MonoclonalHIV AntibodiesHIV Envelope Protein gp41Vaccines, SyntheticViral Fusion Proteins

Identifiers

PMID26087072
PMCPMC4472232

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.